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a b s t r a c t
To provide a tool for research on regulating adipocyte differentiation, tetracycline inducible
(Tet on) lentiviral expression vectors under the control of an adipose-specific promoter
were constructed. The lowest basal expression in the absence of doxycycline and most effi-
cient dose-dependent, doxycycline-induced transient overexpression was observed using
vectors constructed with a combination of Tetracycline Responsive Element (TRE) and
reverse tetracycline-controlled TransActivator advanced (rtTAadv), transfected in white
(3T3-L1) and brown (HIB-1B) preadipocytes cell lines. The results demonstrate that doxy-
cycline adipogenic inducible expression can be achieved using a pLenti TRE / rtTA adv
under the control of the truncated aP2 promoter in HIB-1B preadipocytes.
 2012 Elsevier Inc. All rights reserved.
1. Introduction
Adipose tissue is found in two forms, energy-storing
white adipose tissue (WAT), and energy expending brown
adipose tissue (BAT). It has been proposed that the balance
between these two adipose tissue types may contribute
to the development of obesity (Klingenberg, 1999;
Nedergaard et al., 2001). Adipogenesis is controlled by a
complicated regulatory network involving the time-
dependent expression of a series of transcription factors,
co-regulators and signaling pathways (Morrison and Farm-
er, 1999; Rosen and Spiegelman, 2000; Yeh et al., 1995).
Induction of differentiation in white preadipocytes is
orchestrated by the temporal expression of C/EBPb, C/EBPa
and PPARc while brown adipocytes are thought to ema-
nate from a myogenic progenitor as a result of expression
of PRDM16 and C/EBPb (Kajimura et al., 2009, 2008; Seale
et al., 2008). The purpose of the experimental work
reported here was to construct an adipose tissue specific
promoter (aP2) driving a tetracycline inducible (Tet on)
lentiviral expression backbone, so that the vectors can be
used in the future to produce lentiviruses for the construc-
tion of transgenic cell lines.
Tetracycline has been employed to regulate gene
expression by binding to the Tet Operator (tetO) within
the tetracycline response element (TRE) to either switch
off expression (tet-Off) or switch on expression (tet-On).
The Tet On expression system has two essential compo-
nents, the TRE and the reverse tetracycline-controlled
transactivator (rtTA), both of which have evolving design
and sequences. The original TRE-based promoter (Gossen
and Bujard, 1992) confers inducible expression in the pres-
ence of doxycycline but has a relatively high background
transcription (‘‘leakiness’’). The improved TRE promoter,
TRE tight (Clontech) has been suggested to show a greater
response to doxycycline coupled with extremely low basal
transcriptional activity by redesign of the 7 tetO sequences
that make up the TRE and the removal of the potential
binding sites of endogenous transcription factors
(Clontechniques, 2003). The Tet On transactivator rtTA also
has been improved (rtTA advanced also known as
rtTA2S-M2) by utilizing human codon preferences, remov-
ing cryptic splice sites from the mRNA sequences to
increase its sensitivity to doxycycline and significantly
diminish residual binding to TREs in the absence of
doxycycline (Urlinger et al., 2000). Therefore there are
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two versions of TREs and two versions of rtTAs, thus four
different combinations were tested in order to determine
which backbone gave the best doxycycline inducible
expression. Previous studies employing adipose-specific
(adipogenic) expression vectors have used the adipose
tissue specific promoter aP2 promoter (PaP2). However,
the size (5.6 kb) of the aP2 promoter exceeds the maximal
insert size (4–5 kb in total) of pLenti6 destination vector
(Invitrogen), so a 1.2 kb truncated aP2 promoter (P0aP2)
containing only the fat-specific enhancer and the proximal
promoter of the original aP2 promoter (Graves et al., 1992),
was used to generate the vectors for lentivirus production.
2. Materials and methods
2.1. Cell culture, transfection and luciferase assay
3T3-L1 cells (ATCC) and HIB-1B cells (kindly provided
by B. Spiegelman) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% (v/v) fetal bovine serum
(Invitrogen) and 1% (v/v) sodium pyruvate in 5% CO2. Dif-
ferentiated 3T3-L1 cells (dif 3T3-L1) were obtained by
inducing the cells (2 days post-confluence) by 500 lM 3-
isobutyl-1-methylxanthine (IBMX), 250nM dexmethasone
(Dex) and 167 nM insulin in growth medium for 48 h and
then fed with fresh growth medium supplemented with
167 nM insulin for 8 days (Karamanlidis et al., 2007).
For luciferase assay, HIB-1B and 3T3-L1 cells were pas-
saged and plated in 96- and 24- well plates, respectively,
for 24 h before transfection at 70–80% confluence. For
selecting the best inducible lentiviral expression backbone,
the constitutive or inducible LucGFP lentiviral expression
vector (100 ng/well in 96-well plate and 300 ng/well for
24-well plate) was transfected to above cells with Fuge-
neHD (Roche) according to the manufacturer’s instruc-
tions. Twenty-four hour after transfection, 1 lg/ml
doxycycline was added to the cells to induce LucGFP
expression, and treated for 24 h. For selecting the best adi-
pogenic lentiviral expression backbone, the PaP2 or P
0
aP2
driving inducible LucGFP lentiviral expression vectors
were transfected into the plated cells with or without the
co-overexpression of C/EBPb and PPARc (50 ng/well for
24-well plate) using FugeneHD. Twenty-four hour post
transfection, 10 lM rosiglitazone and/or 1 lg/ml doxycy-
cline (Dox) was added to the cells and treated for 24 h. If
needed, 10 lM forskolin was added to the cells 36 h
post-transfection and treated for 12 h. The cells were then
assayed by Firefly Luciferase Assay System (Promega).
Cotransfection with a Renilla control plasmid was omitted
from this series of experiments as each vector was com-
pared with its own no doxycycline control, the plasmid
vectors were of similar sizes and no variations in transfec-
tion efficiency were predicted, as supported by the rela-
tively small standard error of the mean values.
2.2. Plasmids used in this study
pLenti6/V5 lentiviral expression backbone was from
Invitrogen. The templates for cloning TRE and TRE tight,
pL3-TRE-LucGFP-2L (Plasmid 11685) and pTRE-Tight
miR-1 (Plasmid 14896), respectively, and the template
for cloning PaP2 and P
0
aP2, pBS-aP2 (Plasmid 11424) all
came from Addgene. The template for cloning rtTA, pTet
On was from Clontech and the template for cloning rtTA
adv, PB-CA-rtTA advance was from Addgene. The overex-
pression vectors pcDNA3.1-C/EBPb (Plasmid 12557) and
pcDNA-PPARc (Plasmid 8895) were also from Addgene.
2.3. Construction of Tet on and fat-specific Tet on Luciferase-
GFP (LucGFP) lentiviral expression vectors
The 3-fragment MultiSite Gateway (Invitrogen) clon-
ing system was used to create Luciferase-GFP (LucGFP) fu-
sion protein lentiviral expression vectors, so the reporter
gene LucGFP, transactivator and the promoter driving
transactivator could be simultaneously cloned into the
modified Tet On lentiviral destination vector. The con-
structed vectors were identified by restriction digest and
vector sequencing. The Tet On vectors worked as illus-
trated in Fig. 1.
2.3.1. Construction of Tet on lentiviral destination vectors
The tetracycline response element (TRE) and the
improved version TRE tight were amplified by PCR from
pL3-TRE-LucGFP-2L and pTRE-Tight miR-1 respectively,
and ClaI and SpeI restriction sites were added to the 50 and
30 end of the PCR products (primer sequences in Table 1).
The digested (ClaI + SpeI) PCR products and pLenti6/V5
plasmid were then ligated to create new Tet on lentiviral
destination vectors, pLenti TRE and pLenti TRE tight.
2.3.2. Construction of short aP2 promoter (P0aP2) template
vector
The fat-specific enhancer and the proximal promoter of
aP2 were amplified by PCR from pBS-aP2 vector (primer
sequences in Table 1), and NotI restriction site was added
to both 50 and 30 ends of the PCR product, which was
digested with NotI and self-circulated to generate the
pBS-aP20 template vector for amplifying P0aP2.
2.3.3. Entry clones for 3-fragment MultiSite Gateway
recombination
Entry clones of LucGFP, rtTA or rtTA adv and PCMV, PaP2
or P0aP2 were created by BP reactions according to the pro-
tocol from Invitrogen. PCR primers for amplifying each tar-
get sequence and adding recombination sites (att sites)
were listed in Table 1.
2.3.4. Construction of lentiviral expression vectors
LR reactions were performed according to the protocol
from Invitrogen, to construct the lentiviral expression
vectors.
Entry clones of LucGFP, PCMV and rtTA and the original
pLenti6/V5 destination vector were used to generate con-
stitutive LucGFP lentiviral expression vector, pLenti-
LucGFP (Fig. 2A). Entry clones of LucGFP, PCMV and rtTA
or rtTA adv and the Tet on lentiviral destination vectors
(pLenti TRE or pLenti TRE tight) were used to generate
Tet on LucGFP lentiviral expression vectors (Fig. 2B). Entry
clones of LucGFP, PaP2 or P
0
aP2 and rtTA adv and the desti-
nation vector pLenti TRE or pLenti TRE tight were used to
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Fig. 1. Schematic working process of Tet On lentiviral expression vectors. The TRE is located upstream of the CMV promoter (PCMV) driving the target gene
LucGFP which is silent in the absence of activation by the reverse tetracycline-controlled transactivator (rtTA). The rtTA is transcribed and translated and
binds to the TRE but only activates transcription of the target gene LucGFP in the presence of Dox.
Table 1
Primer sequences for cloning.
Target Primer sequence (50-30) Flanking inserts Template
TRE F acgaagttatATCGATgaaccccttcc ClaI site pL3-TRE-LucGFP-2L
R ccaagcttagaACTAGTggatcggtcccggtgtcttc SpeI site
TRE tight F ccccgggATCGATggccctttcgtcttcactcgag ClaI site pTRE-Tight miR-1
R ccccgggACTAGTgcgatctgacggttcactaaac SpeI site
pBS-aP20 F cccggGCGGCCGCccaacccaaaccaaacaaagccaaac NotI site pBS-aP2
R cccggGCGGCCGCggttctgactcctggcctgaacttc NotI site
LucGFP F GGGG ACA AGT TTG TAC AAA AAA GCA GGC Tccaccatggaagacgccaaaaac attB1 site pL3-TRE-LucGFP-2L
R GGGG AC AAC TTT GTA TAG AAA AGT TGG Gtgagaagagggacagctatgac attB4 site
PCMV F GGGG ACA ACT TTT CTA TAC AAA GTT Gtattggctcatgtccaacattaccgcc attB4r site pL3-TRE-LucGFP-2L
R GGGG AC AAC TTT ATT ATA CAA AGT TGTgagctctgcttatatagacctcc attB3r site
PaP2 F GGGG ACA ACT TTT CTA TAC AAA GTT Gatatcgaattcccagcaggaatcaggtagc attB4r site pBS-aP2
R GGGG AC AAC TTT ATT ATA CAA AGT T GTctgcagcacaggagggtgctatgagcc attB3r site
P0aP2 F GGGG ACA ACT TTT CTA TAC AAA GTT Gatatcgaattcccagcaggaatcaggtagc attB4r site pBS-aP2
0
R GGGG AC AAC TTT ATT ATA CAA AGT T GTctgcagcacaggagggtgctatgagcc attB3r site
rtTA F GGGG ACA ACT TTG TAT AAT AAA GTT Gatccagcctccgcggccccg attB2 site pTet-on
R GGGG AC CAC TTT GTA CAA GAA AGC TGG GTAgcttggtcgagctgatacttcccgtcc attB3 site
rtTA adv F GGGG ACA ACT TTG TAT AAT AAA GTT Ggcaggcttcaccatgtctagactggac attB2 site PB-CA-rtTA advance
R GGGG AC CAC TTT GTA CAA GAA AGC TGG GTAggtcgagggatcttcataagagaagaggg attB3 site
Fig. 2. Schematic of the lentiviral LucGFP expression vectors. (A) The constitutive pLenti LucGFP expression vector was created by 3-fragment MultiSite
Gateway cloning system (LR reaction) using pLenti6/V5 and entry clones of LucGFP, P0CMV and rtTA. (B) The TRE (1, 3) or TRE tight (2, 4) element was
inserted upstream of the CMV promoter (PCMV) in the pLenti6/V5 vector using BamHI and XhoI. The LucGFP, P
0
CMV and rtTA or rtTA adv entry clones were
cloned into the modified backbones by LR reaction. (C) The full length (PaP2) or truncated (P
0
aP2) aP2 promoter was inserted upstream of the transactivator
rtTA adv element in either the TRE or TRE tight PCMV / LucGFP pLenti backbone by the 3-fragment MultiSite Gateway
 cloning system.
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generate adipocyte-specific inducible lentiviral expression
vectors (Fig. 5).
2.4. Quantitative real time PCR
Total RNA was isolated using Trizol Reagent (Invitro-
gen) according to the manufacturer’s instructions. A
0.2 lg sample of total RNA was employed for cDNA synthe-
sis using the Omniscript Reverse Transcriptase Kit (Qia-
gen), with Random Primer (Promega). For amplification
of aP2 cDNA, the primer sequences were 50-AGCATCA-
TAACCCTAGATGG-30 (forward) and 50-GAAGTCACGCCTTT-
CATAAC-30 (reverse), and the expected size of the PCR
product was 128 bp. The cDNA was amplified in a 15 ll
reaction with LightCycler 480 DNA SYBR Green I Master
Mix (Roche). LightCycler 480 Instrument was used to per-
form the PCR reactions with the following temperature
profile: an initial denaturation temperature at 95 C for
15 min, 35 cycles of denaturation (20 s at 95 C), annealing
(20 s at 58 C) and extension (20 s at 72 C). The data
acquisition was performed during the extension period
and a melting curve was acquired between 72 C and
95 C to check for primer dimers or other non-specific
amplicons. The specificity of PCR products were also
checked by agarose gel electrophoresis. The results were
normalized against 36B4 housekeeping gene expression
and calculated using D (DCt) method.
2.5. Statistical analysis
Data in Figures is presented as average ± SEM from 2 or
3 independent replicate experiments with duplicate or
triplicate wells in each experiment. Effects of treatments
were determined by performing Student’s t-test or Analy-
sis of Variance (ANOVA) as indicated in individual Fig-
ure legend. Significance was accepted if P < 0.05. All
statistical analyses were performed on SPSS statistical
package version 16 (SPSS Inc. Chicago, IL, USA).
3. Results and discussion
3.1. Comparison of inducible lentiviral LucGFP expression
vectors
The four Tet On inducible pLenti LucGFP expression
vectors constructed using different versions of TRE and
rtTA (Fig. 2), were transiently transfected into 3T3-L1 and
HIB-1B preadipocytes on separate occasions. Cells
were treated with 1 lg/ml doxycycline (Dox) 24 post-
transfection and then cultured for 24 h before luciferase
assay to compare the response to Dox above baseline.
The combinations of TRE and rtTA, and TRE tight and rtTA,
resulted in poor responses to Dox above baseline, in both
3T3-L1 and HIB-1B cells (Fig. 3A). The vectors constructed
using TRE and rtTA advance, and TRE tight rtTA advance
exhibited low basal activity in the absence of Dox and
the induced activity in the presence of Dox (5.5 and 6-fold
induced, respectively, P < 0.05) were comparable with the
constitutive (non-inducible) vector in 3T3-L1 cells
(Fig. 3A). In HIB-1B cells (Fig. 3B), the vector combining
TRE with rtTA advance had a low basal activity and better
Fig. 3. Comparison of different Tet on LucGFP vectors (CMV driven) by
luciferase assay in 3T3-L1 (A) and HIB-1B (B) preadipocytes. HIB-1B and
3T3-L1 preadipocytes were transiently transfected with different Tet On
CMV-LucGFP vectors, the empty vector pLenti TRE (negative control) or
the constitutive vector pLenti-LucGFP (CMV, positive control). Cells were
given 1 lg/ml doxycycline (Dox) 24 h post-transfection and cultured for
24 h. Luciferase activity was expressed as fold change relative to the value
from the cells transfected with pLenti TRE tight-LucGFP-rtTA adv vector
without doxycycline induction. Results represent mean ± S.E.M from 2
independent replicate experiments performed in triplicate wells. Stu-
dent’s t-test was used to analyze the data. ⁄P < 0.05 with respect to basal
TRE rtTA; #P < 0.05 with respect to the same vector without Dox
treatment.
Fig. 4. The Tet on LucGFP vectors responded to doxycycline in a dose-
dependent manner. 3T3-L1 preadipocytes were transfected with either
TRE LucGFP rtTA adv or TRE tight LucGFP rtTA adv vector. Doxycycline
was added into the cells 24 h post-transfection at the concentration
indicated in the graph. Firefly luciferase activity was measured 24 h after
the addition of doxycycline. The error bars represent S.E.M from 2
independent replicate experiments performed in triplicate wells.
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Dox induciblity (7.7-fold induced, P < 0.05), but the abso-
lute value of induced luciferase activity was only half of
the constitutive vector. Similar to the result in 3T3-L1,
pLentiTRE tight LucGFP rtTA advance in HIB-1B cells also
had relative low leakiness and good inducibility (6.2-fold
induced, P < 0.05), and the induced luciferase activity was
nearly double that of the constitutive vector value. The re-
sults demonstrated clearly that the improved version of
transactivator rtTA adv could significantly decrease the ba-
sal expression of the vectors in the absence of Dox, com-
pared with the original transactivator rtTA. In terms of
the absolute expression level in presence of Dox, the com-
bination of TRE with rtTA adv performed slightly better
than the combination of TRE tight with rtTA adv in 3T3-
L1 cells, but in HIB-1B cells the Dox induced expression le-
vel of TRE + rtTA adv was much lower than that of TRE
tight + rtTA adv, which might reflect the various sensitivity
of different cell lines to the elements involved in the Tet on
response.
Expression of Tet on vectors can be induced by Dox in a
dose-dependent manner (Tang et al., 2009), so dose re-
sponse experiments using the two most responsive vectors
(TRE / rtTA adv and TRE tight / rtTA adv) were performed in
the 3T3-L1 cell line (Fig. 4). The results demonstrated that
the TRE LucGFP rtTA adv vector was more sensitive to low
concentrations of doxycycline than TRE tight LucGFP rtTA
adv vector, since the luciferase activity was upregulated
12 and 5-fold, respectively, at 1 lg/ml Dox. Above
1 lg/ml Dox, the response of both vectors was more vari-
able and the induction using 8 lg/ml of Dox was reduced,
compared to that using 2–3 lg/ml suggesting possible
toxic effects of higher concentrations of Dox in this cell line
(Fig. 4).
3.2. Comparison of aP2 inducible lentiviral LucGFP expression
vectors
In order to evaluate vectors employing different forms
of the adipogenic-specific aP2 promoter it was first neces-
sary to establish the conditions capable of inducing expres-
sion of aP2 within 48 h, in transiently transfected confluent
preadipocytes. Preliminary experiments were performed
to measure changes in aP2 mRNA when adipocytes were
stimulated by adding a cocktail of two drugs previously
shown to initiate adipogenesis namely 10 lM rosiglitazone
(a PPARc agonist) (Lehrke and Lazar, 2005) and 10 lM for-
skolin (an activator of the b-adrenergic signaling down-
stream target adenylyl cyclase) (Yarwood et al., 1995).
aP2 expression in HIB-1B cells treated for 24 h with rosig-
litazone and forskolin was increased by 65-fold (P < 0.001)
compared with the controls (Fig. 5A), but the same exper-
iment in 3T3-L1 cells only increased aP2 expression by
around 4-fold (P < 0.05) (Fig. 5A). Since expression of
C/EBPb and PPARc both play critical roles in the early
adipogenic programme in 3T3-L1 cells (Lane et al., 1999;
Tontonoz et al., 1994), a further experiment was performed
to examine the induction of aP2 gene expression by tran-
siently overexpressing C/EBPb and PPARc in 3T3-L1 cells
which were treated with 10 lM rosiglitazone over a 48 h
period. aP2 gene expression was stimulated 3–4-fold
(P < 0.05) by co-overexpression of C/EBPb and PPARc
Fig. 5. Adipogenic stimulation of aP2 expression by acute treatment of
3T3-L1 and HIB-1B cells. 10 lM rosiglitazone (Rosi) were added to
confluent HIB-1B and 3T3-L1 (A) cells and 10 lM forskolin (Fsk) was
added to the culture 12 h later. RNA was extracted from the cells 12 h
after adding forskolin and aP2 mRNA expression levels in treated 3T3-L1
and HIB-1B cells was determined by quantitative real time PCR and
normalized against 36B4 housekeeping gene expression. (B) 3T3-L1
preadipocytes were transfected with C/EBPb and PPARc by FugeneHD.
10 lM rosiglitazone (Rosi) were added into the cells 24 h post-transfec-
tion and RNA was extracted from the cells 24 h after adding rosiglitazone.
(C) The differentiated 3T3-L1 cells (dif 3T3-L1) were derived from a
standard differentiated protocol outlined in the Methods section. The
level of aP2 mRNA in treated cells was determined by quantitative real
time PCR and normalized against 18s housekeeping gene expression,
relative to the value from the 14 h pcDNA transfected cells. Each bar
represents the mean ± S.E.M from 2 independent replicate experiments
performed in duplicate wells. (A) ⁄P < 0.05 by Student’s t-test with respect
to controls. (B) (C) Student’s t-test: ⁄P < 0.05 caused by time of Rosi
treatment or differentiation with respect to the control at 14 h; #P < 0.05
caused by overexpression with respect to the control at the same time
point.
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compared to transfected control cells (Fig. 5B), with this
response being maximal at 24 h after the addition of
rosiglitazone. This level of aP2 induction was more than a
hundred fold less than that observed in 3T3-L1 cells
10 days after inducing differentiation using the standard
differentiation protocol (IBMX, Dex and insulin) as
described in the Methods section (Karamanlidis et al.,
2007), indicating that the cells were early in the differenti-
ation programme (Fig. 5C).
The four vectors employing the two successful combi-
nations of Tet on elements described above (TRE / rtTA
adv or TRE tight / rtTA adv) in which the rtTA adv was con-
trolled either by the full length aP2 promoter (PaP2) or a
truncated promoter (P0ap2) constituting the enhancer and
proximal promoter elements (Fig. 2), were transiently
transfected into 3T3-L1 cells. Relative to the cells without
any induction (control cells), addition of Dox stimulated
a 4-fold increase in promoter activity from the PaP2 and
TRE / rtTA adv combination vector (Fig. 6A; P < 0.05). This
effect was further accentuated in 3T3-L1 cells treated to
adipogenic induction (co-overexpression of C/EBPb and
PPARc plus rosiglitazone treatment), with Dox treatment
inducing a 9-fold increase in promoter activity relative to
control cells (P < 0.001). The vector combining PaP2 and
TRE tight / rtTA adv was induced 4-fold by Dox
(P < 0.001; Fig. 6A) however adipogenic induction treat-
ment had no further stimulatory effect. In the vectors con-
structed with truncated aP2 promoter (P0aP2), neither the
TRE-rtTA adv nor TRE tight rtTA adv combination were able
to respond to doxycycline or adipogenic treatment to the
Fig. 6. Activity of adipogenic and doxycycline inducible lentiviral LucGFP
expression vectors in 3T3-L1. The inducible LucGFP lentiviral vectors with
full length aP2 promoter (Tet On PaP2 vectors, A) or with truncated aP2
promoter (Tet on P0aP2 vectors, B) were co-overexpressed with C/EBPb and
PPARc into 3T3-L1 preadipocytes. 10 lM rosiglitazone (Rosi) and 1 lg/ml
doxycycline (Dox) were added to the cells 24 h post-transfection as
indicated and treated for 24 h before luciferase assay. Firefly luciferase
activity was interpreted relative to the control value (no co-overexpres-
sion, no drug treatments) of each group. Each bar represents the
mean ± S.E.M from 2 independent replicate experiments performed in
triplicate wells. Data was analyzed by two-way ANOVA for each lentiviral
vector to examine the effects of Dox treatment and application of
adipogenic conditions (C/EBPb + PPARc co-expression + Rosi treatment).
(A) TRE PaP2 (left): Dox (P < 0.001) and adipogenic condition (P < 0.001)
both significantly increased PaP2 activity and there was no interaction
(P = 0.18) between the two treatments; TRE tight PaP2 (right): Dox
(P < 0.001) significantly increased PaP2 activity while adipogenic condi-
tions had no effect (P = 0.31) and there was no interaction (P = 0.091). (B)
Neither Dox nor adipogenic condition treatment had significant effects on
P0aP2 activity.
Fig. 7. Activity of adipogenic and doxycycline inducible lentiviral LucGFP
expression vectors in 3T3-L1 and HIB-1B preadipocytes. The two fat
specific expression vectors, pLenti TRE-LucGFP PaP2 rtTA adv and pLenti
TRE-LucGFP P0aP2 rtTA adv were transiently expressed into HIB-1B (A) or
3T3-L1 (B) preadipocytes. 10 lM Rosiglitazone (Rosi) and 10 lM forskolin
(Fsk), as indicated, were added to the cells 24 and 36 h post-transfection
respectively. 1 lg/ml doxycycline (Dox) was added to the cells 24 h post-
transfection to induce the expression of the Tet on vectors. Luciferase
assay was carried out 48 h after transfection and firefly luciferase activity
was interpreted relative to the control value (no Rosi, no Fsk, and no Dox)
of each group. Each bar represents the mean ± S.E.M from 2 independent
replicate experiments performed in triplicate wells. Data was analyzed by
two-way ANOVA with each lentiviral vector. (A) left: no interaction
between Dox and Fsk + Rosi treatments (P = 0.111) but Dox (P < 0.001)
and Fsk + Rosi (P < 0.001) both independently increased PaP2 activity;
right: no interaction between Dox and Fsk + Rosi treatments (P = 0.459)
while Dox (P < 0.001) and Fsk + Rosi (P = 0.008) both independently
increased P0aP2 activity. (B) No interaction between Dox and Fsk + Rosi
treatments (P > 0.05) and Dox and fsk + Rosi independently increased
both PaP2 and P
0
aP2 activity (P < 0.001).
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extent observed with the full length aP2 promoter
(Fig. 6B). When the aP2 promoter was induced by com-
bined induction with rosiglitazone and forskolin, there
was a 15-fold induction of luciferase activity in HIB-1B
cells transiently transfected with TRE-rtTA adv under the
control of either PaP2, or P
0
aP2, in response to Dox (Fig. 7A;
P < 0.001). The same experiments in 3T3-L1 cells showed
lower responses (3–4-fold) to Dox and smaller responses
to adipogenic induction using rosiglitazone and forskolin
(Fig. 7B).
3.3. Discussion
This study demonstrates clear differences in basal and
Dox induced expression in vectors constructed using dif-
ferent combinations of tetracycline response elements
(TRE or TRE tight) with reverse tetracycline-controlled
transactivators (rtTA or rtTA adv) transiently transfected
into white (3T3-L1) and brown (HIB-1B) preadipocytes.
The most efficient Dox inducibility with the lowest basal
expression was achieved with an expression construct
combining TRE and rtTA adv, (i.e. pLentiTRE-LucGFP rtTA
adv) in both cell types. There are two potential reasons
responsible for differences in basal expression, 1) the resid-
ual binding of rtTA to tetO sequence of TRE in the absence
of inducer ligand doxycycline (Baron and Bujard, 2000) and
2) the basal transcriptional activity of the tetracycline
responsive promoter even without binding to rtTA. Replac-
ing the TRE with TRE tight (the latter was supposed to be a
more tightly controlled tetracycline response element), did
not improve the inducibility but the basal activity was
slightly reduced (Fig. 3), indicating that the residual bind-
ing of rtTA to tetO sequence is the primary reason contrib-
uting to the ‘‘leakiness’’ of the vectors. Replacing the
original rtTA with rtTA adv, which contains specific muta-
tions that both increase its sensitivity to doxycycline and
significantly diminish residual binding to tetO sequence
in the absence of inducer ligand (Urlinger et al., 2000),
greatly improved the inducibility of the Tet on vectors with
lower basal activity (50% decreased) and produced a much
higher induced expression (7–8-fold)(Fig. 3). (Urlinger
et al., 2000) reported that rtTA gave poor responses in
some cell lines with a relatively low sensitivity toward
Dox, therefore the lack of (or poor) induction with the rtTA
vector was not surprising. It was concluded that the most
efficient response to Dox with the lowest basal expression
was found using a combination of TRE and rtTA adv in both
3T3-L1 and HIB-1B cells.
When the adipogenic promoters were introduced into
the inducible expression vectors, the difference between
the two inducible backbones was even more obvious.
3T3-L1 cells expressing the full length PaP2 driving TRE rtTA
advance vector, in the presence of doxycycline and adipo-
genic induction (overexpression of C/EBPb, PPARc in the
presence of rosiglitazone), demonstrated a 9-fold increase
in luciferase activity compared to unstimulated control
cells. In contrast the luciferase activity of PaP2 driving TRE
tight rtTA adv vector was increased only 3-fold by doxycy-
cline treatment and this response was not affected in cells
exposed to the adipogenic conditions (Fig. 6A). This
difference demonstrated that some specific regulatory
sequences in the TRE tight element might influence the
activity of PaP2.
Rosiglitazone and forskolin treatment was able to suc-
cessfully induce expression 15-fold when the TRE / rtTA
advance vector was placed under the control of either the
full length PaP2 or truncated P
0
aP2, transfected into HIB-1B
cells and stimulated with Dox (Fig. 7A). However in 3T3-
L1 cells, the truncated P0aP2 TRE / rtTA advance vector
construct was not significantly increased by adipogenic
stimulation (Figs. 6 and 7B). It is well known that differen-
tiation of 3T3-L1 cells requires a critical early phase of
mitotic clonal expansion (MCE), when the confluent
growth arrested cells re-enter cell cycle and prepare for
the differentiation for 48 h (Tang et al., 2003). It has been
demonstrated that the MCE is a prerequisite for differenti-
ation of 3T3-L1 preadipocytes to adipocytes, but the differ-
entiation of HIB-1B preadipocytes does not require this
phase. This difference could possibly explain why the same
adipogenic induction conditions worked well in HIB-1B but
had poor effect in 3T3-L1 preadipocytes since the MCE was
omitted as it would not have allowed measurement of the
reporter expression from the transiently transfected
vectors. A further limitation of the study was that the
adipose-specific nature of the constructs was not tested
in other cell lines.
3.4. Conclusion
We have constructed an inducible LucGFP expression
vector comprising of LucGFP regulated by TRE-PCMV and in-
duced by rtTA regulated by the truncated aP2 promoter.
This expression construct gave low basal, high Dox induc-
ibility under adipogenic conditions when transiently trans-
fected into HIB-1B brown preadipocytes.
Acknowledgments
The project was supported by Biotechnology and Bio-
logical Sciences Research Council (BBSRC). Q.L. was sup-
ported by a China Scholarship (The University of
Nottingham).
References
Baron, U., Bujard, H., 2000. Tet repressor-based system for regulated gene
expression in eukaryotic cells: principles and advances. Methods
Enzymol. 327, 401–421.
Clontechniques 2003. pTRE-Tight vector. Clontechniques XVIII (2), 2.
Gossen, M., Bujard, H., 1992. Tight control of gene expression in
mammalian cells by tetracycline-responsive promoters. Proc. Natl.
Acad. Sci. USA. 89, 5547–5551.
Graves, R.A., Tontonoz, P., Platt, K.A., Ross, S.R., Spiegelman, B.M., 1992.
Identification of a fat cell enhancer: analysis of requirements for
adipose tissue-specific gene expression. J. Cell. Biochem. 49, 219–224.
Kajimura, S., Seale, P., Kubota, K., Lunsford, E., Frangioni, J.V., Gygi, S.P.,
Spiegelman, B.M., 2009. Initiation of myoblast to brown fat switch by
a PRDM16-C/EBP-beta transcriptional complex. Nature 460, 1154–
1158.
Kajimura, S., Seale, P., Tomaru, T., Erdjument-Bromage, H., Cooper, M.P.,
Ruas, J.L., Chin, S., Tempst, P., Lazar, M.A., Spiegelman, B.M., 2008.
Regulation of the brown and white fat gene programs through a
PRDM16/CtBP transcriptional complex. Genes Dev. 22, 1397–1409.
Karamanlidis, G., Karamitri, A., Docherty, K., Hazlerigg, D.G., Lomax, M.A.,
2007. C/EBPbeta reprograms white 3T3-L1 preadipocytes to a Brown
adipocyte pattern of gene expression. J. Biol. Chem. 282, 24660–
24669.
102 Q. Liu et al. / Plasmid 69 (2013) 96–103
Klingenberg, M., 1999. Uncoupling protein–a useful energy dissipator. J.
Bioenerg. Biomembr. 31, 419–430.
Lane, M.D., Tang, Q.Q., Jiang, M.S., 1999. Role of the CCAAT enhancer
binding proteins (C/EBPs) in adipocyte differentiation. Biochem.
Biophys. Res. Commun. 266, 677–683.
Lehrke, M., Lazar, M.A., 2005. The many faces of PPARgamma. J. Cell.
Biochem. 123, 993–999.
Morrison, R.F., Farmer, S.R., 1999. Insights into the transcriptional control
of adipocyte differentiation. J. Cell. Biochem. 32–33, 59–67, Suppl..
Nedergaard, J., Golozoubova, V., Matthias, A., Asadi, A., Jacobsson, A.,
Cannon, B., 2001. UCP1: the only protein able to mediate adaptive
non-shivering thermogenesis and metabolic inefficiency. Biochim.
Biophys. Acta 1504, 82–106.
Rosen, E.D., Spiegelman, B.M., 2000. Molecular regulation of adipogenesis.
Annu. Rev. Cell Dev. Biol. 16, 145–171.
Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., Scime, A.,
Devarakonda, S., Conroe, H.M., Erdjument-Bromage, H., et al., 2008.
PRDM16 controls a brown fat/skeletal muscle switch. Nature 454,
961–967.
Tang, H., Liu, L., Liu, F.J., Chen, E.Q., Murakami, S., Lin, Y., He, F., Zhou, T.Y.,
Huang, F.J., 2009. Establishment of cell lines using a doxycycline-
inducible gene expression system to regulate expression of hepatitis
B virus X protein. Arch. Virol. 154, 1021–1026.
Tang, Q.Q., Otto, T.C., Lane, M.D., 2003. Mitotic clonal expansion: a
synchronous process required for adipogenesis. Proc. Natl. Acad. Sci.
USA. 100, 44–49.
Tontonoz, P., Hu, E., Spiegelman, B.M., 1994. Stimulation of adipogenesis
in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.
J. Cell. Biochem. 79, 1147–1156.
Urlinger, S., Baron, U., Thellmann, M., Hasan, M.T., Bujard, H., Hillen, W.,
2000. Exploring the sequence space for tetracycline-dependent
transcriptional activators: novel mutations yield expanded range
and sensitivity. Proc. Natl. Acad. Sci. USA. 97, 7963–7968.
Yarwood, S.J., Anderson, N.G., Kilgour, E., 1995. Cyclic AMP modulates
adipogenesis in 3T3-F442A cells. Biochem. Soc. Trans. 23, 175S.
Yeh, W.C., Cao, Z., Classon, M., McKnight, S.L., 1995. Cascade regulation of
terminal adipocyte differentiation by three members of the C/EBP
family of leucine zipper proteins. Genes Dev. 9, 168–181.
Q. Liu et al. / Plasmid 69 (2013) 96–103 103
